Audentes Therapeutics (NASDAQ:BOLD) Downgraded by BidaskClub

BidaskClub cut shares of Audentes Therapeutics (NASDAQ:BOLD) from a strong-buy rating to a buy rating in a report issued on Saturday, June 29th, BidAskClub reports.

Several other research firms have also recently issued reports on BOLD. BMO Capital Markets cut Capital Power from an outperform rating to a market perform rating in a research note on Wednesday, May 8th. Svb Leerink upped their price objective on Audentes Therapeutics from $37.00 to $48.00 and gave the company an outperform rating in a report on Wednesday, April 17th. ValuEngine lowered Zymeworks from a buy rating to a hold rating in a report on Saturday, May 18th. Leerink Swann restated an outperform rating and issued a $48.00 price objective (up previously from $37.00) on shares of Audentes Therapeutics in a report on Wednesday, April 17th. Finally, HC Wainwright set a $31.00 target price on Kura Oncology and gave the company a buy rating in a report on Wednesday, May 8th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have assigned a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $39.99.

BOLD traded down $0.18 during trading on Friday, reaching $37.90. 304,044 shares of the company were exchanged, compared to its average volume of 471,933. The firm has a market capitalization of $1.68 billion, a PE ratio of -11.15 and a beta of 1.70. The business’s 50 day moving average price is $37.42. Audentes Therapeutics has a 52 week low of $17.95 and a 52 week high of $42.69.

Audentes Therapeutics (NASDAQ:BOLD) last issued its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($1.13) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.90) by ($0.23). During the same period in the previous year, the company posted ($0.74) earnings per share. As a group, analysts forecast that Audentes Therapeutics will post -4.43 earnings per share for the current year.

In other news, Director Louis G. Lange sold 21,000 shares of the stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $37.79, for a total transaction of $793,590.00. Following the transaction, the director now owns 290,001 shares of the company’s stock, valued at approximately $10,959,137.79. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Suyash Prasad sold 10,000 shares of the stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $36.98, for a total value of $369,800.00. Following the transaction, the vice president now directly owns 28,236 shares in the company, valued at approximately $1,044,167.28. The disclosure for this sale can be found here. 5.30% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of BOLD. Great Point Partners LLC acquired a new position in shares of Audentes Therapeutics during the 4th quarter valued at about $35,346,000. Partner Fund Management L.P. boosted its stake in Audentes Therapeutics by 94.4% during the 4th quarter. Partner Fund Management L.P. now owns 3,021,259 shares of the biotechnology company’s stock valued at $64,413,000 after purchasing an additional 1,467,120 shares during the period. Gilder Gagnon Howe & Co. LLC boosted its stake in Audentes Therapeutics by 913.5% during the 1st quarter. Gilder Gagnon Howe & Co. LLC now owns 1,619,831 shares of the biotechnology company’s stock valued at $63,206,000 after purchasing an additional 1,459,999 shares during the period. BB Biotech AG bought a new stake in Audentes Therapeutics during the 4th quarter valued at approximately $16,404,000. Finally, Millennium Management LLC bought a new stake in Audentes Therapeutics during the 4th quarter valued at approximately $12,600,000. 98.71% of the stock is currently owned by institutional investors and hedge funds.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Recommended Story: What is the NASDAQ Stock Market?

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.